Becton, Dickinson and Company $BDX Stock Purchased by Glenview Trust Co

Glenview Trust Co grew its holdings in shares of Becton, Dickinson and Company (NYSE:BDX) by 6.5% in the third quarter, HoldingsChannel.com reports. The fund owned 76,949 shares of the medical instruments supplier’s stock after purchasing an additional 4,707 shares during the period. Glenview Trust Co’s holdings in Becton, Dickinson and Company were worth $13,774,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Brown Lisle Cummings Inc. increased its position in shares of Becton, Dickinson and Company by 9.2% in the second quarter. Brown Lisle Cummings Inc. now owns 644 shares of the medical instruments supplier’s stock worth $97,000 after purchasing an additional 54 shares during the last quarter. Pension & Wealth Management Advisors Inc. grew its stake in Becton, Dickinson and Company by 12.3% in the 3rd quarter. Pension & Wealth Management Advisors Inc. now owns 510 shares of the medical instruments supplier’s stock worth $94,000 after buying an additional 56 shares in the last quarter. Elevation Point Wealth Partners LLC increased its holdings in shares of Becton, Dickinson and Company by 3.7% in the 2nd quarter. Elevation Point Wealth Partners LLC now owns 1,692 shares of the medical instruments supplier’s stock worth $256,000 after buying an additional 60 shares during the last quarter. Private Harbour Investment Management & Counsel LLC raised its position in shares of Becton, Dickinson and Company by 1.1% during the 2nd quarter. Private Harbour Investment Management & Counsel LLC now owns 5,511 shares of the medical instruments supplier’s stock valued at $834,000 after buying an additional 62 shares in the last quarter. Finally, Trifecta Capital Advisors LLC raised its position in shares of Becton, Dickinson and Company by 59.0% during the 3rd quarter. Trifecta Capital Advisors LLC now owns 167 shares of the medical instruments supplier’s stock valued at $30,000 after buying an additional 62 shares in the last quarter. Hedge funds and other institutional investors own 86.97% of the company’s stock.

Analysts Set New Price Targets

BDX has been the subject of a number of research analyst reports. Weiss Ratings raised shares of Becton, Dickinson and Company from a “sell (d+)” rating to a “hold (c-)” rating in a report on Monday, September 28th. Citigroup reissued a “buy” rating on shares of Becton, Dickinson and Company in a research note on Thursday, August 13th. Wolfe Research began coverage on Becton, Dickinson and Company in a research report on Tuesday, October 20th. They set an “outperform” rating on the stock. TD Cowen lifted their price target on Becton, Dickinson and Company from $163.00 to $182.00 and gave the stock a “hold” rating in a research note on Wednesday, August 5th. Finally, Evercore set a $180.00 price objective on Becton, Dickinson and Company in a report on Monday, July 6th. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, eight have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $185.07.

Insider Activity at Becton, Dickinson and Company

In related news, EVP Michael Feld sold 165 shares of the stock in a transaction dated Wednesday, August 26th. The stock was sold at an average price of $188.49, for a total transaction of $31,100.85. Following the completion of the sale, the executive vice president directly owned 19,720 shares in the company, valued at $3,717,022.80. This represents a 0.83% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Roland Goette sold 2,438 shares of the firm’s stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $180.84, for a total value of $440,887.92. Following the transaction, the executive vice president owned 14,856 shares in the company, valued at approximately $2,686,559.04. The trade was a 14.10% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 6,907 shares of company stock worth $1,269,128 in the last ninety days. 0.40% of the stock is owned by company insiders.

Becton, Dickinson and Company Price Performance

Shares of NYSE:BDX opened at $197.48 on Friday. The company has a quick ratio of 0.51, a current ratio of 0.87 and a debt-to-equity ratio of 0.55. The stock has a market cap of $54.41 billion, a PE ratio of 59.48, a PEG ratio of 13.37 and a beta of 0.21. The company’s fifty day moving average is $186.58 and its 200 day moving average is $170.26. Becton, Dickinson and Company has a 52 week low of $127.59 and a 52 week high of $200.47.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.14 by $0.09. Becton, Dickinson and Company had a net margin of 4.52% and a return on equity of 14.79%. The business had revenue of $4.98 billion during the quarter, compared to analyst estimates of $4.89 billion. During the same period in the prior year, the business posted $3.68 earnings per share. The company’s revenue was up 5.4% on a year-over-year basis. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. Research analysts anticipate that Becton, Dickinson and Company will post 12.67 earnings per share for the current year.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company, commonly known as BD, is a global medical technology company that develops, manufactures and sells a broad range of products used by healthcare providers, clinical laboratories, pharmaceutical companies and patients. Its offerings support medication delivery, diagnostics, infection prevention, surgical care and other clinical procedures.

BD’s products include needles, syringes, injection devices, intravenous administration systems, medication-management technologies, specimen-collection products, diagnostic systems and laboratory instruments.